In RA, Tofacitinib Has Higher Infection Rate Than TNFi

Patients with rheumatoid arthritis are at greater risk for infection if they’re treated with tofacitinib than with a tumor necrosis factor inhibitor (TNFi), according to an industry-funded study.
MDedge News